Every Form 4 that Xeris Biopharma Holdings (XERS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow XERS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XERS filings page.
Xeris Biopharma Holdings, Inc. (XERS) reported that President and Chief Operating Officer Kevin McCulloch sold 15,000 shares of common stock on September 1, 2026 at a weighted average price of $8.4872 per share, pursuant to a Rule 10b5-1 trading plan adopted on September 4, 2025. Following this sale, he directly holds 1,639,208 shares of common stock and has indirect holdings of 25,000 shares held by his spouse, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.
Xeris Biopharma Holdings, Inc. (XERS) insider Beth Hecht, Chief Legal Officer and Corporate Secretary, reported selling 16,666 shares of common stock on 2026-09-01 in an open-market transaction under a Rule 10b5-1 trading plan adopted on 2025-08-08. The weighted average sale price was $8.4864 per share, from multiple trades between $8.390 and $8.600. Following this sale, Hecht directly holds 1,127,796 shares of XERS common stock.
Xeris Biopharma Holdings, Inc. (XERS) reported that Chief Financial Officer Steven Pieper sold 5,000 shares of common stock on September 1, 2026 at a price of $8.50 per share. After this transaction, he directly holds 1,356,053 shares of XERS common stock. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on August 18, 2025.
Xeris Biopharma Holdings, Inc. (XERS) reported that its Chief Executive Officer and Chairman, Shannon John Patrick Jr, had 36,645 shares of common stock withheld on August 1, 2026. The shares were withheld by the company to satisfy income tax and withholding obligations upon net settlement of vested restricted stock units, not as an open-market sale. After this tax-withholding transaction, Patrick Jr directly holds 2,898,933 shares of XERS common stock.
Xeris Biopharma Holdings, Inc. (XERS) reported an insider equity-tax event by President and Chief Operating Officer Kevin McCulloch. On August 1, 2026, 21,918 shares of common stock were withheld by the company at $8.08 per share to satisfy income tax and withholding obligations on vested restricted stock units. After this tax-withholding disposition, McCulloch directly held 1,654,208 shares of common stock. An additional 25,000 shares are reported as indirectly owned by his spouse, with McCulloch disclaiming beneficial ownership except to the extent of his pecuniary interest.
Xeris Biopharma Holdings, Inc. reported that its Chief Financial Officer, Steven Pieper, sold 5,000 shares of common stock on August 12, 2026 at a price of $8.50 per share. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on August 18, 2025. Following this sale, Pieper continues to hold 1,361,053 shares of Xeris Biopharma common stock directly.
Kevin McCulloch, President and Chief Operating Officer of Xeris Biopharma Holdings, Inc., sold 15,000 shares of common stock on August 3, 2026 at a weighted average price of about $8.016 per share under a Rule 10b5-1 trading plan adopted on September 4, 2025, and now reports 1,676,126 shares held directly plus 25,000 shares held indirectly through his spouse, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.
Xeris Biopharma Holdings, Inc. reported that Chief Legal Officer and Corporate Secretary Beth Hecht sold 16,666 shares of common stock on August 3, 2026, in a sale classified as an open-market or private transaction at a weighted average price of $8.0135 per share. The transaction was effected under a Rule 10b5-1 trading plan adopted on August 8, 2025. Following this sale, she directly owned 1,144,462 shares of common stock. The shares were sold in multiple trades at prices between $7.870 and $8.140 per share.
Xeris Biopharma Holdings insider Steven Pieper reported open-market sales of 45,000 shares of common stock over two days. He sold 27,600 shares on July 7, 2026 at a weighted average price of $8.5245 per share and 17,400 shares on July 6, 2026 at $8.50 per share.
After these transactions, Pieper directly holds 1,366,053 Xeris Biopharma shares. The filing notes the trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 18, 2025, and that his holdings include 2,113 shares acquired on June 30, 2026 through the company’s Employee Stock Purchase Plan.
Xeris Biopharma Holdings director Nerissa Kreher received equity-based compensation. She was granted 33,582 shares of common stock through restricted stock units under the company’s 2018 Stock Option and Incentive Plan. These RSUs vest in equal annual installments over three years, contingent on continued board service.
She was also granted stock options for 37,910 shares of common stock at an exercise price of $8.00 per share, expiring on July 1, 2036. These options vest in equal annual installments over three years, also subject to continued service on the board. The filing shows no open-market buying or selling, only compensation-related awards.
Xeris Biopharma Holdings officer Kevin McCulloch reported an open-market sale of 90,000 shares of common stock at a weighted average price of $8.0279 per share on July 1, 2026. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2025.
After the transaction, McCulloch directly owns 1,691,126 shares of Xeris Biopharma common stock. An additional 25,000 shares are held indirectly by his spouse, including 3,401 shares acquired on June 30, 2026 under the company’s 2018 Employee Stock Purchase Plan, with beneficial ownership of those indirect shares disclaimed except for any pecuniary interest.
Xeris Biopharma Holdings, Inc. officer Beth Hecht reported an open-market sale of 16,666 shares of common stock at a weighted average price of $8.0319 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 8, 2025.
After this sale, Hecht directly holds 1,161,128 Xeris Biopharma shares, indicating she retains a substantial equity position. Her holdings include 1,288 shares acquired on June 30, 2026 under the company’s 2018 Employee Stock Purchase Plan, showing ongoing participation in employee ownership programs.
Xeris Biopharma Holdings, Inc. director Garheng Kong reported receiving new equity awards as part of his compensation. He was granted 24,193 shares of common stock in the form of restricted stock units under the company’s 2018 Stock Option and Incentive Plan. Following this award, his direct common stock holdings total 238,337 shares.
He also received a stock option for 32,996 shares of common stock with an exercise price of $6.15 per share, expiring on June 4, 2036. Both the restricted stock units and the stock options vest in full on the earlier of June 4, 2026 or the date of the company’s next annual meeting of stockholders, provided he continues to serve through the vesting date.
Xeris Biopharma Holdings director Marla Persky reported both equity awards and a share sale. On June 4, 2026, she received 24,193 shares of Common Stock via a restricted stock unit grant that vests in full on the earlier of June 4, 2026 or the company’s next annual stockholders meeting, subject to continued service.
She also received 32,996 stock options with an exercise price of $6.15 per share, vesting on the same schedule and expiring on June 4, 2036. A day earlier, on June 3, 2026, she sold 15,500 shares of Common Stock in open-market transactions at a weighted average price of $5.8989 per share under a pre-arranged Rule 10b5-1 trading plan, leaving 150,693 shares held directly after the awards. The filing also shows 6,370 shares held indirectly through the Marla Susan Persky Revocable Trust, with beneficial ownership disclaimed except to the extent of pecuniary interest.
Xeris Biopharma director Dawn Halkuff reported a mix of equity grants and a pre-planned share sale. She received 24,193 shares of common stock as a restricted stock unit grant and 32,996 stock options at $6.15 per share, both vesting in full on the earlier of June 4, 2026 or the company’s next annual stockholder meeting, subject to continued service. On the same date, she sold 20,000 shares of common stock at a weighted average price of $6.0943 per share under a Rule 10b5-1 trading plan adopted on September 4, 2025, and held 95,000 shares directly afterward. She also had 5,410 shares held indirectly through the Dawn Halkuff Revocable Trust, for which she disclaims beneficial ownership except to the extent of her pecuniary interest.
Xeris Biopharma Holdings director Barbara-Jean Anne Bormann-Kennedy reported a mix of equity awards and a stock sale. She received 24,193 shares of common stock as a restricted stock unit grant under the company’s 2018 Stock Option and Incentive Plan, at no cash cost.
She also received stock options for 32,996 shares of common stock at an exercise price of $6.15 per share, expiring on June 4, 2036. Both the restricted stock and the options vest in full on the earlier of June 4, 2026 or the company’s next annual meeting of stockholders, subject to continued service.
On the same date, she sold 16,000 shares of common stock in an open-market transaction at a weighted average price of $6.0942 per share, executed pursuant to a Rule 10b5-1 trading plan adopted on September 12, 2025. After these transactions, she holds 150,693 common shares directly.
Xeris Biopharma Holdings director John Johnson reported a mix of equity awards and a pre-planned share sale. He received 24,193 shares of common stock through a restricted stock unit grant and 32,996 stock options with a $6.15 exercise price, both vesting in full on the earlier of June 4, 2026 or the company’s next annual stockholder meeting, subject to continued service.
On the same date, he sold 15,000 common shares at a weighted average price of $6.0948 per share under a Rule 10b5-1 trading plan adopted on August 13, 2025. After these transactions, he directly holds 707,276 common shares and 32,996 stock options.
Xeris Biopharma Holdings director Brady James Aloysius received new equity awards. He was granted 24,193 shares of common stock through restricted stock units under the 2018 Stock Option and Incentive Plan, bringing his direct holdings to 113,359 shares.
He was also granted stock options for 32,996 shares of common stock at an exercise price of $6.15 per share, expiring on June 4, 2036. Both the restricted stock units and options vest in full on the earlier of June 4, 2026 or the company’s next annual meeting of stockholders, subject to his continued service.
Xeris Biopharma Holdings officer Beth Hecht reported an open-market sale of Company stock. She sold 16,667 shares of common stock at a weighted average price of $6.0588 per share under a pre-arranged Rule 10b5-1 trading plan. After this transaction, she continues to hold 1,176,506 shares directly.
Xeris Biopharma Holdings officer Beth Hecht completed an open-market sale of 16,667 shares of common stock at a weighted average price of $6.2282 per share. After the sale, she directly holds 1,193,173 shares. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Xeris Biopharma Holdings, Inc. officer Beth Hecht reported an open-market sale of 16,667 shares of common stock at a weighted average price of $5.9914 per share. After this transaction, she directly owns 1,209,840 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan.
Xeris Biopharma Holdings director Brady James Aloysius sold 10,834 shares of common stock in an open-market transaction. The shares were sold at a weighted average price of $5.5414 per share under a Rule 10b5-1 trading plan. Following the sale, he directly holds 89,166 shares. The sale price reflects multiple trades in a range from $5.29 to $5.63 per share.
Xeris Biopharma Holdings, Inc. officer Kevin McCulloch exercised stock options to acquire a total of 48,898 shares of common stock on March 12, 2026, at exercise prices of $4.09 and $3.94 per share. These options were granted under the company’s 2018 Stock Option/Stock Issuance Plan and had fully vested based on prior service conditions. Following the transactions, he holds 1,777,725 common shares directly and 25,000 shares indirectly through his spouse. The filing notes he disclaims beneficial ownership of some reported securities beyond his pecuniary interest.
Xeris Biopharma Holdings reported that officer Steven Pieper exercised stock options and acquired common shares. On March 5, 2026, he converted options into 27,891 common shares at $4.09 per share and 14,036 common shares at $5.93 per share through derivative exercises.
These options were originally granted on January 31, 2018 and December 10, 2020 under company stock option plans with vesting tied to continued employment. Following the transactions, he directly owned up to 1,408,940 common shares.
Xeris Biopharma Holdings, Inc. reported that company officer Beth Hecht executed two open-market sales of its common stock under a pre-established Rule 10b5-1 trading plan. She sold a total of 16,667 shares on March 2, 2026, at prices including $6.2401 and $7.06 per share, and held 1,226,507 shares afterward.
Xeris Biopharma Holdings, Inc. officer Anh Tu Nguyen reported a Form 4 transaction where 29,300 shares of common stock were withheld by the company at $6.88 per share to cover income tax obligations on vested restricted stock units as of February 24, 2026.
After this tax-withholding disposition, Nguyen directly owned 395,023 shares of common stock, with additional indirect holdings of 3,710 shares through an IRA and 3,501 shares through children’s IRAs, for which he disclaims full beneficial ownership beyond his pecuniary interest.
Xeris Biopharma Holdings, Inc. director and Chief Executive Officer Shannon John Patrick Jr reported equity compensation and related tax-withholding activity in company stock. On January 30, 2026, he received 478,436 shares of common stock for $0, issued as restricted stock units that vest in equal annual installments over three years, subject to continued employment. On the same date, he was granted 639,639 stock options with a $7.36 exercise price, also vesting in equal annual installments over three years and expiring on January 30, 2036. On January 31, 2026, the company withheld blocks of common shares at $7.36 per share to cover income tax and withholding obligations tied to vested restricted stock units. After these transactions, he directly owned 2,935,578 shares of common stock and 639,639 stock options.
Xeris Biopharma Holdings, Inc. executive equity activity: President and Chief Operating Officer Kevin McCulloch reported new stock-based compensation and related tax share withholdings. On January 30, 2026, he received 168,463 shares of common stock through a restricted stock unit grant that vests in three equal annual installments, subject to continued employment.
On the same date, he was granted 225,225 stock options with a $7.36 exercise price, also vesting in three equal annual installments, subject to continued service. On January 31, 2026, the company withheld 68,454, 30,289, and 27,319 shares at $7.36 per share to cover income tax obligations on vested restricted stock units. After these transactions, he directly owned 1,727,827 common shares.
The filing also notes 25,000 shares held indirectly by his spouse, with McCulloch disclaiming beneficial ownership except to the extent of his pecuniary interest.
Xeris Biopharma Holdings reported insider equity awards and related tax share withholding for Chief Financial Officer Steven Pieper. On January 30, 2026, he received 154,986 shares of common stock through a restricted stock unit grant under the 2018 Stock Option and Incentive Plan, vesting in equal annual installments over three years, subject to continued employment.
On the same date, he was granted 207,207 stock options with an exercise price of $7.36 per share, also vesting annually over three years and expiring on January 30, 2036. On January 31, 2026, a total of 206,?
Xeris Biopharma Holdings Chief Medical Officer Nguyen Anh Tu reported new equity awards. On January 30, 2026, he received 121,293 shares of common stock through a restricted stock unit grant and 162,162 stock options with a $7.36 exercise price.
The restricted stock units and stock options each vest in equal annual installments over three years, conditioned on continued employment or service. Following the grant, he directly holds 424,323 shares of common stock and 162,162 options, plus indirect holdings of common stock through an IRA and a children's IRA, for which he disclaims beneficial ownership beyond his economic interest.
Xeris Biopharma Holdings’ Chief Legal Officer and Corporate Secretary Beth Hecht reported multiple equity transactions in XERS stock. On January 30, 2026, she received 121,293 shares of common stock via restricted stock units and a grant of 162,162 stock options under the company’s 2018 Stock Option and Incentive Plan, both vesting in equal annual installments over three years.
On January 31, 2026, a total of shares were withheld at $7.36 per share to cover taxes on vested restricted stock units. On February 2, 2026, she sold 16,667 shares of common stock at a weighted average price of $7.4487 per share pursuant to a pre-arranged Rule 10b5-1 trading plan, leaving her with 1,243,174 shares of directly owned common stock.
Xeris Biopharma Holdings, Inc. officer Kevin McCulloch reported selling 15,000 shares of common stock at $8.00 per share on January 8, 2026. The sale was executed under a Rule 10b5-1 trading plan adopted by the reporting person. After this transaction, he beneficially owned 1,685,426 shares of common stock directly and 25,000 shares indirectly through his spouse. He serves as President and Chief Operating Officer of the company.
Xeris Biopharma Holdings director reports preset stock sale. An Xeris Biopharma Holdings, Inc. director reported selling 15,000 shares of common stock on 12/12/2025, identified with transaction code "S." The shares were sold at a weighted average price of $7.0943 per share.
The disclosure states the transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After this sale, the director beneficially owns 142,500 shares of Xeris Biopharma common stock directly.
Xeris Biopharma Holdings (XERS) filed a Form 4 showing option exercises and a share sale by its Chief Executive Officer and Director. On 11/13/2025, the reporting person exercised stock options to acquire 8,970 shares of common stock at an exercise price of $1.55 per share and sold 23,242 shares of common stock at a weighted average price of $7.4607, all under a pre-arranged Rule 10b5-1 trading plan. After these transactions on that date, the reporting person held 2,643,153 shares of common stock directly. On 11/14/2025, the reporting person exercised additional stock options for 87,100 shares at $1.55 per share, increasing the directly held common stock position to 2,730,253 shares. Following these transactions, the person also held 64,265 stock options with an exercise price of $1.55 per share expiring on 02/03/2027.
Xeris Biopharma (XERS) reported an insider transaction by an officer. On 11/11/2025, the reporting person sold 16,667 shares of common stock at a weighted average price of $7.3976, executed under a Rule 10b5-1 trading plan.
Following the sale, the filer directly beneficially owned 1,336,843 shares. The sale price reflects multiple trades between $7.290 and $7.750. The reporting person is the company’s Chief Legal Officer and Corporate Secretary.
Xeris Biopharma Holdings insider Kevin McCulloch, listed as President and Chief Operating Officer, reported a transaction dated 10/02/2025. The filing shows 733 shares of common stock were disposed of at $8.31; the explanation states these shares were withheld by the issuer to satisfy tax and withholding obligations in connection with the net settlement of restricted stock units that vested on that date. After the reported transaction, Mr. McCulloch beneficially owns 1,700,426 shares directly. The report also lists 25,000 shares held indirectly by his spouse, with the reporting person disclaiming beneficial ownership except for pecuniary interest.
Xeris Biopharma Holdings, Inc. (XERS) Form 4 discloses insider reporting by Kevin McCulloch, President and Chief Operating Officer. On September 11, 2025 Mr. McCulloch, acting as trustee of the Charles R. McCulloch Trust, caused the trust to distribute 2,000 shares of Xeris common stock to a trust beneficiary; the Form notes no sale occurred in the transfer. The filing reports Mr. McCulloch's beneficial ownership following the transaction as 1,701,159 shares and an indirect holding of 25,000 shares attributable to his spouse. The reporting person disclaims beneficial ownership of distributed shares except to the extent of pecuniary interest.